BCA
TXG icon

Berman Capital Advisors’s 10x Genomics TXG Stock Holding History

Berman Capital Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$36K Buy
251
+116
+86% +$19.9K 0.01% 806
2021
Q2 		$25K Buy
135
+43
+47% +$7.78K ﹤0.01% 833
2021
Q1 		$16K Buy
+92
New +$15.9K ﹤0.01% 874

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
MCAV
Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Berman Capital Advisors's TXG Position: Q3 2021 in Review

Berman Capital Advisors increased its 10x Genomics (TXG) stake by 86% in Q3 2021, buying an estimated $19.9K and bringing the position to 251 shares worth $36K. The position accounts for 0.01% of the portfolio, ranked #806.

Berman Capital Advisors first reported a position in TXG in Q1 2021 and has held it in 3 quarters since. 330 funds tracked by Wall St. Rank hold TXG as of Q3 2021.

  • Berman Capital Advisors held 251 shares of 10x Genomics worth $36K as of Q3 2021.
  • Berman Capital Advisors bought 116 10x Genomics shares in Q3 2021, an estimated $19.9K.
  • 10x Genomics made up 0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #806 holding.
  • Berman Capital Advisors first reported a position in 10x Genomics in Q1 2021 and has held it in 3 quarters since.
  • 330 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.